Australia markets closed
  • ALL ORDS

    7,624.30
    +23.80 (+0.31%)
     
  • ASX 200

    7,368.90
    +9.90 (+0.13%)
     
  • AUD/USD

    0.7487
    -0.0064 (-0.85%)
     
  • OIL

    71.50
    +0.46 (+0.65%)
     
  • GOLD

    1,763.90
    -10.90 (-0.61%)
     
  • BTC-AUD

    47,719.70
    -1,195.21 (-2.44%)
     
  • CMC Crypto 200

    888.52
    -51.42 (-5.47%)
     
  • AUD/EUR

    0.6308
    -0.0028 (-0.44%)
     
  • AUD/NZD

    1.0787
    +0.0009 (+0.09%)
     
  • NZX 50

    12,551.93
    +10.73 (+0.09%)
     
  • NASDAQ

    14,049.58
    -114.22 (-0.81%)
     
  • FTSE

    7,017.47
    -135.96 (-1.90%)
     
  • Dow Jones

    33,290.08
    -533.37 (-1.58%)
     
  • DAX

    15,448.04
    -279.63 (-1.78%)
     
  • Hang Seng

    28,801.27
    +242.68 (+0.85%)
     
  • NIKKEI 225

    28,964.08
    -54.25 (-0.19%)
     

Global Gastro-Intestinal Stromal Tumors Markets, Epidemiology and Patient Flow Report 2020-2035 - ResearchAndMarkets.com

·2-min read

The "Global Gastro-Intestinal Stromal Tumors Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com's offering.

Global Gastro-Intestinal Stromal Tumors Epidemiology and Patient Flow Analysis - 2021, provides Gastro-Intestinal Stromal Tumors epidemiology, demographics, and patient flow. The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.

The research provides population data to characterize Gastro-Intestinal Stromal Tumors patients, history of the disease at the population level (Gastro-Intestinal Stromal Tumors prevalence, Gastro-Intestinal Stromal Tumors incidence) and at the clinical level (from diagnosis to treated patients). It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.

Research scope:

  • Gastro-Intestinal Stromal Tumors patient flow: Gastro-Intestinal Stromal Tumors prevalence, diagnosed, and drug-treated patients

  • Countries: US, Germany, France, Italy, Spain, UK, Japan, G7 Countries

  • Demographics: Gastro-Intestinal Stromal Tumors patients by age group, gender

  • Forecast: Gastro-Intestinal Stromal Tumors epidemiology forecast to 2035

The data from this research will help executives:

  • Establish basis for Gastro-Intestinal Stromal Tumors market sizing, assessing market potential, and developing drug forecast models

  • Identify Gastro-Intestinal Stromal Tumors patients segments through age groups, gender, and disease sub-types

  • Develop Gastro-Intestinal Stromal Tumors population-based health management frameworks

  • Evaluate Gastro-Intestinal Stromal Tumors market opportunities, identify target patient population

  • Align marketing decisions with the Gastro-Intestinal Stromal Tumors target population

  • Communicate leadership and health authorities about your Gastro-Intestinal Stromal Tumors target patient population

Key Topics Covered:

1. Research Methodology

2. Gastro-Intestinal Stromal Tumors Patients Definition

3. US Gastro-Intestinal Stromal Tumors Epidemiology and Patient Flow

4. Germany Gastro-Intestinal Stromal Tumors Epidemiology and Patient Flow

5. France Gastro-Intestinal Stromal Tumors Epidemiology and Patient Flow

6. Italy Gastro-Intestinal Stromal Tumors Epidemiology and Patient Flow

7. Spain Gastro-Intestinal Stromal Tumors Epidemiology and Patient Flow

8. UK Gastro-Intestinal Stromal Tumors Epidemiology and Patient Flow

9. Europe Gastro-Intestinal Stromal Tumors Epidemiology and Patient Flow

10. Japan Gastro-Intestinal Stromal Tumors Epidemiology and Patient Flow

11. Global Gastro-Intestinal Stromal Tumors Epidemiology and Patient Flow

For more information about this report visit https://www.researchandmarkets.com/r/d9iql3

View source version on businesswire.com: https://www.businesswire.com/news/home/20210512005844/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting